Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply

Michael Weller; Nicholas Butowski; David D. Tran; Lawrence D. Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A. Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M. O'Rourke; Mark Wong; Mark G. Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D. Turner; Michael J. Yellin; Tibor Keler; Thomas A. Davis; Roger Stupp; John H. Sampson

doi:10.1016/S1470-2045(17)30856-2

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply

Michael Weller, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A. Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M. O'Rourke, Mark Wong, Mark G. Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D. TurnerMichael J. Yellin, Tibor Keler, Thomas A. Davis, Roger Stupp, John H. Sampson

Fondazione IRCCS Istituto Neurologico "C. Besta"

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e709-e710
Journal	The Lancet Oncology
Volume	18
Issue number	12
DOIs	https://doi.org/10.1016/S1470-2045(17)30856-2
Publication status	Published - Dec 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(17)30856-2

Cite this

Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, M., Hamilton, M. G., Finocchiaro, G., Perry, J., Wick, W., Green, J., He, Y., ... Sampson, J. H. (2017). Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. The Lancet Oncology, 18(12), e709-e710. https://doi.org/10.1016/S1470-2045(17)30856-2

Go, no-go decision making for phase 3 clinical trials : ACT IV revisited – Authors' reply. / Weller, Michael; Butowski, Nicholas; Tran, David D.; Recht, Lawrence D.; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A.; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M.; Wong, Mark; Hamilton, Mark G.; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer; He, Yi; Turner, Christopher D.; Yellin, Michael J.; Keler, Tibor; Davis, Thomas A.; Stupp, Roger; Sampson, John H.

In: The Lancet Oncology, Vol. 18, No. 12, 01.12.2017, p. e709-e710.

Research output: Contribution to journal › Letter › peer-review

Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O'Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R & Sampson, JH 2017, 'Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply', The Lancet Oncology, vol. 18, no. 12, pp. e709-e710. https://doi.org/10.1016/S1470-2045(17)30856-2

Weller, Michael ; Butowski, Nicholas ; Tran, David D. ; Recht, Lawrence D. ; Lim, Michael ; Hirte, Hal ; Ashby, Lynn ; Mechtler, Laszlo ; Goldlust, Samuel A. ; Iwamoto, Fabio ; Drappatz, Jan ; O'Rourke, Donald M. ; Wong, Mark ; Hamilton, Mark G. ; Finocchiaro, Gaetano ; Perry, James ; Wick, Wolfgang ; Green, Jennifer ; He, Yi ; Turner, Christopher D. ; Yellin, Michael J. ; Keler, Tibor ; Davis, Thomas A. ; Stupp, Roger ; Sampson, John H. / Go, no-go decision making for phase 3 clinical trials : ACT IV revisited – Authors' reply. In: The Lancet Oncology. 2017 ; Vol. 18, No. 12. pp. e709-e710.

@article{7e8e266ae195490aa19725c36783296e,

title = "Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply",

author = "Michael Weller and Nicholas Butowski and Tran, {David D.} and Recht, {Lawrence D.} and Michael Lim and Hal Hirte and Lynn Ashby and Laszlo Mechtler and Goldlust, {Samuel A.} and Fabio Iwamoto and Jan Drappatz and O'Rourke, {Donald M.} and Mark Wong and Hamilton, {Mark G.} and Gaetano Finocchiaro and James Perry and Wolfgang Wick and Jennifer Green and Yi He and Turner, {Christopher D.} and Yellin, {Michael J.} and Tibor Keler and Davis, {Thomas A.} and Roger Stupp and Sampson, {John H.}",

year = "2017",

month = dec,

day = "1",

doi = "10.1016/S1470-2045(17)30856-2",

language = "English",

volume = "18",

pages = "e709--e710",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Go, no-go decision making for phase 3 clinical trials

T2 - ACT IV revisited – Authors' reply

AU - Weller, Michael

AU - Butowski, Nicholas

AU - Tran, David D.

AU - Recht, Lawrence D.

AU - Lim, Michael

AU - Hirte, Hal

AU - Ashby, Lynn

AU - Mechtler, Laszlo

AU - Goldlust, Samuel A.

AU - Iwamoto, Fabio

AU - Drappatz, Jan

AU - O'Rourke, Donald M.

AU - Wong, Mark

AU - Hamilton, Mark G.

AU - Finocchiaro, Gaetano

AU - Perry, James

AU - Wick, Wolfgang

AU - Green, Jennifer

AU - He, Yi

AU - Turner, Christopher D.

AU - Yellin, Michael J.

AU - Keler, Tibor

AU - Davis, Thomas A.

AU - Stupp, Roger

AU - Sampson, John H.

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85035348037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035348037&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30856-2

DO - 10.1016/S1470-2045(17)30856-2

M3 - Letter

AN - SCOPUS:85035348037

VL - 18

SP - e709-e710

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -